Fosamax Missed-Dose Protocol: What to Do When You Skip Alendronate

The Standard Missed-Dose Rule for Weekly Alendronate

The FDA-approved prescribing information for alendronate 70 mg weekly states a simple protocol: if you forget your scheduled dose, take one tablet the morning after you remember, then return to your original day of the week [1]. Do not take two tablets on the same day or within a short window.

Why "Next Morning" and Not "Right Now"

Alendronate requires an empty stomach and at least 30 minutes of upright positioning to reduce esophageal irritation. Taking a tablet at midday or bedtime violates these absorption and safety requirements. The "next morning" instruction ensures the patient can follow the full administration protocol: wake, take the tablet with 8 oz of plain water, remain upright, and wait 30 minutes before eating or drinking anything else [1].

Returning to Your Regular Schedule

After taking the make-up dose, skip ahead or wait until your next originally scheduled day. If your normal day is Monday and you remember on Wednesday morning, take the dose Wednesday. The following week, resume on Monday. The goal is to avoid two doses within 24 to 48 hours rather than maintain a perfect 7-day interval. A 5-day or 9-day gap between doses is clinically acceptable, given the drug's long residence time in bone [2].

When You Miss More Than One Week

Two consecutive missed weeks still fall within a recoverable window. Take one dose the next morning you remember and resume the weekly cycle. If three or more weeks have passed, the same rule applies, but you should notify your prescriber. Prolonged gaps may warrant a conversation about whether the medication is working, whether an alternative dosing format (IV zoledronic acid, given once yearly) would improve adherence, or whether the treatment plan needs reassessment [3].

How Alendronate Works and Why One Missed Dose Is Not a Crisis

Understanding alendronate's pharmacology explains why a single skipped dose causes minimal harm. The drug belongs to the nitrogen-containing bisphosphonate class and acts by inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway that osteoclasts need to function [4].

Binding to Bone Mineral

After oral absorption (bioavailability is roughly 0.7% under fasting conditions), alendronate circulates briefly and then binds avidly to hydroxyapatite at sites of active bone remodeling. Once incorporated, the drug has an estimated skeletal half-life of approximately 10 years [2]. This means that missing one weekly dose does not leave bone suddenly unprotected. The drug reservoir already embedded in bone continues to suppress osteoclast activity between doses.

Osteoclast Suppression Mechanism

When osteoclasts resorb bone containing alendronate, they internalize the drug. Alendronate disrupts intracellular signaling by inhibiting FPPS, which prevents prenylation of small GTPases (Ras, Rho, Rac) essential for osteoclast survival and function [4]. The osteoclast loses its ruffled border, detaches from the bone surface, and undergoes apoptosis. This mechanism is dose-dependent but also cumulative: drug deposited over weeks and months creates a reservoir that continues to release during resorption.

The Practical Implication

A patient who has been adherent for six months has a substantial bone reservoir. Skipping a single dose barely changes the amount of drug available to suppress the next wave of osteoclast activity. The concern begins when gaps become frequent or sustained.

What the Evidence Says About Adherence Gaps

The Fracture Intervention Trial (FIT), published in JAMA in 1998, established alendronate's clinical benefit: a 47% reduction in radiographic vertebral fractures and a 51% reduction in hip fractures over 3 years in women with existing vertebral fractures (N=2,027) [5]. Those results depend on consistent dosing.

Adherence Below 80% Erodes Protection

A retrospective cohort study using U.S. Claims data (N=35,537) found that patients with a medication possession ratio (MPR) below 50% had fracture rates nearly identical to untreated patients. Those with MPR between 50% and 80% retained partial but diminished protection. Only patients above 80% adherence achieved fracture reduction comparable to trial populations [6].

A 2004 analysis published in Osteoporosis International examined adherence patterns in 11,249 bisphosphonate users and reported that only 43% of patients remained on therapy at 12 months [7]. Dr. Stuart Silverman, clinical professor of medicine at Cedars-Sinai, has noted: "The greatest pharmacologic advance means nothing if the patient stops taking the drug at six months. Persistence is the rate-limiting step in osteoporosis treatment."

The Refill Gap Problem

The typical pattern is not a single forgotten dose but a gradual drift. A patient forgets one week, then forgets again, then stops refilling. A 2007 analysis in the Journal of Bone and Mineral Research showed that among women who discontinued bisphosphonates, 50% did so within the first year, and fracture risk began rising within 6 to 12 months of discontinuation [8]. The Endocrine Society's 2019 clinical practice guideline recommends that clinicians assess adherence at every follow-up visit and consider switching to IV zoledronic acid (5 mg annually) for patients who cannot maintain oral bisphosphonate schedules [3].

Administration Rules That Affect Missed-Dose Decisions

Alendronate's strict dosing conditions are the main reason people miss doses. Knowing the rules precisely helps prevent errors.

The Fasting Requirement

Take alendronate first thing in the morning on an empty stomach with at least 8 oz (240 mL) of plain water. No coffee, juice, mineral water, or food for at least 30 minutes afterward. Calcium, iron, antacids, and other supplements must wait at least 30 minutes (some guidelines recommend 60 minutes) because divalent cations form insoluble complexes with bisphosphonates and can reduce absorption by over 60% [1][9].

The Upright Positioning Rule

Remain upright (sitting or standing) for at least 30 minutes after swallowing the tablet. Do not lie down. This reduces the risk of esophageal erosion and ulceration. A post-marketing analysis reported to the FDA documented cases of esophageal stricture and erosive esophagitis in patients who took bisphosphonates and then reclined [10]. This is why taking a missed dose at bedtime is explicitly contraindicated.

What Counts as a Dosing Error

Taking the tablet with coffee instead of plain water: dosing error. Lying down within 15 minutes: dosing error. Taking it with a calcium supplement: dosing error. In each case, the recommendation is not to take a second dose to "make up" for reduced absorption. Wait until the next scheduled dose and follow the protocol correctly [1].

Daily vs. Weekly Alendronate: Missed-Dose Differences

Alendronate is available in two regimens: 10 mg daily (less commonly prescribed now) and 70 mg weekly.

Daily Dosing Protocol

If you miss a daily 10 mg dose, skip it entirely and take the next dose the following morning. Do not double up. Because daily dosing provides smaller, more frequent drug delivery, a single missed day represents a smaller fraction of weekly drug exposure. The clinical impact of one missed daily dose is negligible [1].

Weekly Dosing Protocol

The 70 mg weekly tablet delivers the same total weekly exposure as 10 mg daily (70 mg per week either way). Missing a weekly dose means missing 100% of that week's drug delivery rather than ~14%. This is why the labeling specifically instructs patients to take the missed dose the next morning rather than simply skipping to the following week [1].

Which Regimen Has Better Adherence

A head-to-head adherence study (N=1,233) found that 12-month persistence was 44.2% for weekly dosing versus 31.7% for daily dosing [11]. The weekly regimen has become the standard of care partly because of this adherence advantage. The 2019 Endocrine Society guideline endorses weekly oral bisphosphonates over daily formulations for treatment of postmenopausal osteoporosis [3].

Preventing Missed Doses: Practical Strategies

Pharmacologic efficacy depends on the patient actually taking the drug. Several evidence-backed approaches improve adherence.

Anchor the Dose to a Fixed Routine

Choose a consistent day (many patients pick Monday or Sunday). Place the tablet, a glass, and a water bottle on the nightstand the evening before. This environmental cue removes the "did I already take it?" question. A 2009 study in Patient Preference and Adherence found that patients who linked bisphosphonate dosing to a specific weekly routine had 22% higher 12-month persistence compared to those without a fixed cue [12].

Use Phone Alarms or Pill Reminders

Simple, but effective. A randomized trial (N=2,087) testing automated telephone reminders for bisphosphonate users showed a 12-percentage-point improvement in MPR at 12 months compared to usual care [13]. Smartphone alarms accomplish the same function at no cost.

Ask About IV Alternatives if Oral Adherence Fails

Zoledronic acid 5 mg IV once yearly eliminates the daily or weekly burden entirely. The HORIZON-PFT trial (N=7,765) demonstrated 70% reduction in vertebral fracture risk and 41% reduction in hip fracture risk over 3 years [14]. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has stated: "For patients who struggle with the oral bisphosphonate regimen, annual IV zoledronic acid offers equivalent or superior fracture protection with guaranteed adherence at the point of infusion."

Special Populations and Missed-Dose Considerations

Patients on Concomitant Calcium and Vitamin D

Most osteoporosis patients take calcium and vitamin D supplements alongside alendronate. If a patient takes the missed alendronate dose on a non-standard morning, they must still maintain the 30-to-60-minute separation from calcium. Some patients inadvertently take calcium first out of habit, which can nullify the alendronate dose [9].

Patients with GI Conditions

Patients with Barrett's esophagus, active esophageal ulcers, or inability to stand or sit upright for 30 minutes should not take oral bisphosphonates at all, regardless of missed-dose status. These are absolute contraindications listed in the prescribing information [1]. If a patient develops new GI symptoms (dysphagia, retrosternal pain, new heartburn), they should stop the drug and contact their physician before taking any further doses.

Elderly Patients with Cognitive Impairment

Forgetfulness in older adults may signal a need for supervised administration or transition to IV therapy. A caregiver-administered weekly protocol or annual IV infusion can maintain fracture protection in patients who cannot reliably self-administer [3].

Monitoring After Missed Doses

A single missed dose does not require additional lab work or imaging. Repeated gaps (three or more missed doses in a quarter) may prompt your clinician to check bone turnover markers. Serum C-telopeptide (CTX), a marker of bone resorption, should be suppressed in patients on adequate bisphosphonate therapy. A rising CTX level suggests inadequate drug exposure [15].

DXA scans are typically repeated every 1 to 2 years on therapy. If adherence has been inconsistent, a DXA scan can help determine whether bone density is being maintained, declining, or stable enough to consider a drug holiday [3].

Serum 25-hydroxyvitamin D should be checked at baseline and annually. Vitamin D deficiency (below 20 ng/mL) impairs the skeletal response to bisphosphonates, and correcting it is a prerequisite for optimal treatment effect [15].